JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

The Prognostic Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured by 18F-FDG PET/CT in Patients with NSCLC
Received Date : 14 Oct 2021
Accepted Date : 10 Nov 2021
Available Online : 18 Nov 2021
Doi: 10.37047/jos.2021-86651 - Article's Language: EN
J Oncol Sci. 2021;7(3):150-8
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Objective: This study aimsto determine the prognostic value of metabolic volumetric 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) parameters of the primary tumor, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with non-small cell lung cancer (NSCLC) patients. Material and Methods: The study included a total of 102 patients who underwent PET/CT for staging. Histopathological diagnosis, stage of disease, survival time, maximum standard uptake value, MTV, and TLG values of the primary tumor were documented. The Kaplan-Meier test was used to examine the relationships between overall survival (OS) with PET/CT parameters and Tumor-Node-Metastasis stages. Univariate and multivariate Cox regression analyses were applied, and the association between OS with metabolic volumetric PET/CT parameters was estimated. Results: During the follow-up period, 93 (91.17%) patients died. All patients had a median OS of 10.15 months (range 0.5-74 months), whereas patients with M1 disease had a median OS of 7 months (range 0.5-56 months). The majority of (79.41%) patients had advanced-stage disease. Statistically, the mean MTV (p=0.012) and TLG (p=0.037) values at the early stage (Stage I-II) were significantly lower than the locally advanced and advanced (Stage III-IV) stage. In univariate analysis, elder age (p=0.004), advanced stage (p<0.001), lack of the operable (p<0.001), high MTV (p<0.001), and TLG (p<0.001) values were significantly correlated with poor OS. In multivariate analysis, stage of the disease (p<0.05), age (p=0.004), operable (p=0.022), and TLG (p=0.0019) values were found to be the independent predictors for OS. Conclusion: In patients with NSCLC, MTV and TLG of the primary tumor are suitable parameters to predict prognosis at first diagnosis. Particularly high level of TLG was independently related to poor prognosis.
KAYNAKLAR
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. [Crossref]  [PubMed] 
  2. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(28):2518-2527. [Crossref]  [PubMed]  [PMC] 
  3. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193-203. [Crossref]  [PubMed] 
  4. Detterbeck FC, Chansky K, Groome P, et al; IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2016;11(9):1433-1446. [PubMed] 
  5. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995;60(5):1348-1352. [Crossref]  [PubMed] 
  6. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80(6):1046-1051. [Crossref]  [PubMed] 
  7. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130(1): 151-159. [Crossref]  [PubMed] 
  8. Infante JR, Cabrera J, Rayo JI, et al. 18F-FDG PET/CT quantitative parameters as prognostic factor in localized and inoperable lung cancer. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020;39(6):353-359. English, Spanish. [Crossref]  [PubMed] 
  9. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):328-333. [Crossref]  [PubMed] 
  10. Romesser PB, Qureshi MM, Shah BA, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med. 2012; 26(7):527-534. [Crossref]  [PubMed]  [PMC] 
  11. Sharma A, Mohan A, Bhalla AS, et al. Role of various metabolic parameters derived from baseline 18F-FDG PET/CT as prognostic markers in non-small cell lung cancer patients undergoing platinum-based chemotherapy. Clin Nucl Med. 2018;43(1):e8-e17. [Crossref]  [PubMed] 
  12. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1(Suppl 1):122S-150S. [Crossref]  [PubMed]  [PMC] 
  13. Lodge MA. Repeatability of SUV in Oncologic 18F-FDG PET. J Nucl Med. 2017;58(4):523-532. [Crossref]  [PubMed]  [PMC] 
  14. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roent genol. 2010;195(2):310-320. Erratum in: AJR Am J Roentgenol. 2010;195(4):1043. [Crossref]  [PubMed] 
  15. Yamaguchi O, Kaira K, Hashimoto K, et al. Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50. Sci Rep. 2020;10(1):14990. [Crossref]  [PubMed]  [PMC] 
  16. Zhang H, Wroblewski K, Liao S, et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2013;20(1):32-40. [Crossref]  [PubMed] 
  17. Lim CH, Hyun SH, Moon SH, Cho YS, Choi JY, Lee KH. Comparison of prognostic values of primary tumor and nodal 18F-fluorodeoxyglucose uptake in non-small cell lung cancer with N1 disease. Eur Radiol. 2019;29(10):5288-5297. [Crossref]  [PubMed] 
  18. Hyun SH, Ahn HK, Kim H, et al. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41(1): 50-58. [Crossref]  [PubMed] 
  19. Lin Y, Lin WY, Kao CH, Yen KY, Chen SW, Yeh JJ. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer. Anticancer Res. 2012;32(11):5087-5091. [PubMed] 
  20. Lapa P, Marques M, Isidoro J, Barata F, Costa G, de Lima JP. 18F-FDG PET/CT in lung cancer. The added value of quantification. Rev Esp Med Nucl Imagen Mol. 2017;36(6):342-349. English, Spanish. [Crossref]  [PubMed] 
  21. Li Q, Zhang J, Cheng W, et al. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(37):e8084. [Crossref]  [PubMed]  [PMC] 
  22. Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257(2):364-370. [Crossref]  [PubMed] 
  23. Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: A meta-analysis. PLoS One. 2016;11(1):e0146195. [Crossref]  [PubMed]  [PMC] 
  24. Davison J, Mercier G, Russo G, Subramaniam RM. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR Am J Roentgenol. 2013;200(3):635-640. [Crossref]  [PubMed] 
  25. Verma S, Chan J, Chew C, Schultz C. PET-SUV max and upstaging of lung cancer. Heart Lung Circ. 2019;28(3):436-442. [Crossref]  [PubMed] 
  26. Koh YW, Lee SJ, Park SY. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters. Lung Cancer. 2017;104:31-37. [Crossref]  [PubMed]